2026-04-17T11:56:16Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/65612025-10-24T10:19:44Zcom_2072_378070com_2072_378040col_2072_378092

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM) Puertolas, Teresa Riveiro Barciela, Maria del Mar Paredes, Roger Gonzalez-Cao, Maria Ortiz Velez, Carolina Muñoz Couselo, Eva Institut Català de la Salut [Gonzalez-Cao M] Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain. [Puertolas T] Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Aragón, Spain. [Riveiro M] Unitat del Fetge, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Muñoz-Couselo E, Ortiz C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Paredes R] IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain. Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain Vall d'Hebron Barcelona Hospital Campus Càncer - Immunoteràpia DISEASES::Neoplasms Other subheadings::Other subheadings::/therapy ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::/terapia TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia Immunoteràpia Inmunoterapia Immunotherapy Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities. This work was supported by the Spanish Melanoma Group (GEM). 2021-11-17T13:17:42Z 2021-11-17T13:17:42Z 2021-03 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, et al. Cancer immunotherapy in special challenging populations: Recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). J Immunother Cancer. 2021 Mar;9:e001664 2051-1426 https://hdl.handle.net/11351/6561 10.1136/jitc-2020-001664 33782108 000636250800002 http://hdl.handle.net/11351/6561 eng Journal for ImmunoTherapy of Cancer;9 http://dx.doi.org/10.1136/jitc-2020-001664 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess application/pdf application/pdf BMJ Scientia